1. Balfour, H. H., Bean, B., Laskin, O. L., Ambinder, R. F., Meyers, J. D., Wade, J. C., Zaia, J. A., Aeppli, D., Kirk, L. E., Segreti, A. C., Keeney, R. E., and the Burroughs Wellcome Collaborative Acyclovir Study Group, 1983, Acyclovir halts profession of herpes zoster in immunocompromised patients, N. Engl. J. Med. 308:1448–1453.
2. Bodey, G. P., Gottlieb, F., McCredie, K. B., Freireich, E., 1975, Adenine arabinoside in cancer chemotherapy in: Adenine Arabinoside: An Antiviral Agent, pp. 182–285 (D. Pavan-Langston, R. Buchanan, and C. Alford, Jr., eds.), Raven, New York.
3. Boston Interhospital Collaborative and NIAID Sponsored Cooperative Antiviral Clinical Study, 1975, Failure of high dose 5-iodo-2′-deoxyuridine in the therapy of herpes simplex virus encephalitis: evidence of unacceptable toxicity, N. Engl. J. Med. 292:600–603.
4. Bryson, Y. J., Dillon, M., Lovett, M., Acuna, G., Taylor, S., Cherry, J. D., Johnson, B. L., Wiesmeier, E., Growdow, W., Creagh-Kirk, T., and Keeney, R., 1983, Successful treatment of initial genital herpes simplex virus infections with oral acyclovir, N. Engl. J. Med. 308:916–921.
5. Calabresi, P., Carnosos, S. S., Finch, S. C., Kligerman, M. M., Von Essen, C. F., Chu, M. Y., and Welch, A. D., 1961, Initial clinical studies with 5-iodo-2′-deoxyuridine, Cancer Res. 21:550–559.